GrimAge (v1 & v2)

Epigenetic

DNA Methylation Clocks

GrimAge is a DNA methylation clock built to predict time-to-death, using epigenetic surrogates of plasma proteins such as PAI-1 along with smoking-related methylation. It is widely regarded as one of the most clinically relevant mortality-predicting epigenetic clocks. A longevity practice tracks it as a high-level indicator of long-term health risk and how that risk shifts with intervention.

What It Measures

Epigenetic clock predicting time-to-death; based on DNA methylation surrogates of plasma proteins (including PAI-1, cystatin C equivalents); considered the most clinically relevant mortality predictor

Optimal vs. Lab Range

Longevity Optimal

Biological age < chronological age

Target range for optimal health and longevity based on research.

Standard Lab

N/A — compared to chronological age

Population-based reference range from standard labs.

Why It Matters

A GrimAge biological age above your chronological age signals accelerated aging and is associated with higher all-cause mortality and elevated cancer and cardiovascular risk, while a biological age below chronological age is the goal. What distinguishes GrimAge from the other clocks is its foundation in protein surrogates tied directly to mortality, rather than the cumulative epigenetic age captured by Horvath or the clinical-biomarker composite behind PhenoAge. This gives it particular strength as a risk-stratification signal. It complements pace-of-aging measures like DunedinPACE, which track current trajectory rather than lifetime risk. GrimAge remains a research and emerging clinical tool, not a diagnostic certainty.

When Low

N/A — younger biological age is the goal

When High

Accelerated biological aging, higher all-cause mortality, cancer risk, cardiovascular risk

How to Optimize

Lifestyle fundamentals come first: not smoking, regular exercise, caloric restriction or metabolic optimization, quality sleep, and stress reduction, since these influence the inflammatory and metabolic biology GrimAge reflects. Because smoking-related methylation weighs heavily in the algorithm, avoiding tobacco is especially relevant. Investigational agents such as rapamycin and senolytics are being explored in longevity research but remain experimental and physician-directed. Biological-age testing is an emerging tool; interpretation and any interventions should be individualized with your physician; this content is educational and not a substitute for medical advice.

Key Interventions & Linked Compounds

Strong evidence

Key Interventions

Caloric restriction

exercise

sleep

stress reduction

rapamycin (clinical)

senolytics

Linked Compounds & Supplements

NMN

Resveratrol

Fisetin

Spermidine

Metformin

Curated from clinical literature. Individual results vary; consult a qualified clinician before changing a protocol.

Ordering Notes

Specimen

Buccal swab or whole blood (EDTA)

Patient prep

No fasting required. Maintain usual diet and medications unless advised.

Recommended cadence

Annual

Reporting unit

Confirm with the performing lab — units vary by region.

Pre-analytic notes

Standardize draw time of day, hydration, and recent exercise. Note any acute illness, supplements, or hormonal therapies on the requisition.

Recommended Follow-Up Actions

1
Confirm the result is reliable
Repeat abnormal values before acting — preferably from the same lab, same time of day, and under consistent prep. Rule out acute illness, recent intense exercise, or medication effects that can shift GrimAge (v1 & v2).
2
Compare against optimal, not just lab range
Use the optimal window above as the target. Lab "normal" is built from the general population and often misses early dysfunction.
3
Pair with related markers
Order a complementary panel covering metabolic, inflammatory, and hormonal context to interpret this marker properly.
4
Discuss interventions with a clinician
Use the interpretation guidance above to frame the conversation. Bring trends, not just one datapoint, to your visit.
5
Re-test on a defined cadence
If a change is implemented, re-measure in 8–12 weeks for fast-moving markers, or 3–6 months for slower ones, to confirm response before escalating.